Shionogi Reveals Strategy For COVID-19 Drug Xocova
Backups Also In Development
Shionogi is hoping to demonstrate the efficacy of its oral COVID-19 candidate Xocova through an appropriate primary endpoint in its Phase III trial, while the Japanese firm is also eyeing global expansion for the drug should a world-first domestic approval be granted.
You may also be interested in...
A controversial letter from two Japanese doctors' associations seemingly pressing regulators to approve Shionogi’s oral COVID-19 drug prompts a backlash from other physicians.
Japan has approved Evusheld for both the prevention of infection in people who have not been exposed to the virus and, for the first time globally, as a treatment. The country's government will purchase 300,000 units from AZ amid global supplies that have been limited due to the surging need for the drug.
Xocova’s emergency approval stymied by uncertainties over efficacy and other characteristics that could effectively limit its use, prompting decision to await Phase III data later this year.